Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?

Breast cancer (BRCA) mutations account for the highest proportion of hereditary causes of pancreatic ductal adenocarcinoma (PDAC). Screening is currently recommended only for patients with one first‐degree relative or two family members with PDAC. We hypothesized that screening all BRCA1/2 patients would identify a higher rate of pancreatic abnormalities.

[1]  M. Wallace,et al.  Su1007 - Cost-Effectiveness of Pancreatic Cancer Screening in High-risk Individuals: An Economic Analysis , 2018 .

[2]  S. Alkaade,et al.  Frequency and Significance of Abnormal Pancreatic Imaging in Patients with BRCA1 and BRCA2 Genetic Mutations , 2016, Scientifica.

[3]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[4]  B. Arun,et al.  Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian , 2022 .

[5]  R. Gershoni-baruch,et al.  Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers , 2014, British Journal of Cancer.

[6]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[7]  V. Fendrich,et al.  Familial pancreatic cancer—status quo , 2014, International Journal of Colorectal Disease.

[8]  Paul Fockens,et al.  International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer , 2012, Gut.

[9]  Jin-Young Jang,et al.  International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. , 2012, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[10]  Zhe Zhang,et al.  Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. , 2012, Gastroenterology.

[11]  M. Canto,et al.  Pancreatic cancer screening. , 2012, Gastroenterology clinics of North America.

[12]  Martin Krapcho,et al.  SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .

[13]  G. Lahat,et al.  Intraductal papillary mucinous neoplasm of the pancreas: associated cancers, family history, genetic predisposition? , 2012, Surgery.

[14]  Sofia Khan,et al.  Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations , 2011, Familial Cancer.

[15]  E. Smets,et al.  Feasibility of a pancreatic cancer surveillance program from a psychological point of view , 2011, Genetics in Medicine.

[16]  W. Jarnagin,et al.  Feasibility and Yield of Screening in Relatives From Familial Pancreatic Cancer Families , 2011, The American Journal of Gastroenterology.

[17]  D. Gouma,et al.  High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  J. Heverhagen,et al.  Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer , 2009, Gut.

[19]  K. Horton,et al.  Prevalence of unsuspected pancreatic cysts on MDCT. , 2008, AJR. American journal of roentgenology.

[20]  Mariza de Andrade,et al.  The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[21]  J. C. Houwelingen,et al.  Cancer risks in BRCA2 families: estimates for sites other than breast and ovary , 2005, Journal of Medical Genetics.

[22]  A. Ziegler,et al.  BRCA2 germline mutations in familial pancreatic carcinoma. , 2003, Journal of the National Cancer Institute.

[23]  M. Kimmey,et al.  Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. , 2003, Gastrointestinal endoscopy.

[24]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[25]  T. Rebbeck,et al.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. , 2002, Journal of the National Cancer Institute.

[26]  Kathleen M Murphy,et al.  Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. , 2002, Cancer research.

[27]  F. Couch,et al.  BRCA2 and pancreatic cancer , 2002, International journal of gastrointestinal cancer.

[28]  R. Brand,et al.  Hereditary pancreatic adenocarcinoma. A clinical perspective. , 2000, The Medical clinics of North America.

[29]  Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium , 1999 .

[30]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[31]  R H Hruban,et al.  Familial pancreatic cancer: a review. , 1996, Seminars in oncology.

[32]  M M Grajower,et al.  Familial pancreatic cancer. , 1983, Annals of internal medicine.

[33]  H. Lynch,et al.  HEREDITY AND MULTIPLE PRIMARY MALIGNANT NEOPLASMS: SIX CANCER FAMILIES , 1967, The American journal of the medical sciences.